FDA delays approval decision on GSK's $1.9B blood cancer bet

GSK is going to have to wait a little longer to start delivering a return on its $1.9 billion oncology bet. The FDA has delayed its ruling on the blood cancer candidate momelotinib by three months to provide time to review recently submitted data.